Interventions: Drug: CVN424 75 mg Drug: CVN424 150 mg Drug: Placebo Primary Outcome Measures: Change from Baseline to Week 12 in average daily OFF time on motor diaries for 150 mg CVN424 compared to placebo The assessment of the average daily OFF time, normalized to waking hours will be based on diaries completed at home for three consecutive days during the 7-day period before a scheduled in-person visit
Tirzepatide improves physical function Researchers conducted a meta-analysis of six randomized controlled trials involving 4,536 participants and found that those treated with tirzepatide (Zepbound) had substantially better physical function than those receiving placebo
GLP-1 receptors are expressed throughout the brain, and their activation promotes neuronal survival, reduces neuroinflammation, and improves synaptic plasticity
La vida moderna est llena de estrs, lo que resulta en una necesidad alta de Glutatin y de los antioxidantes que optimizan su actividad en el organismo
View product Retatrutide is a 39-amino-acid triple agonist that activates GLP-1, GIP and glucagon receptors simultaneously, modulating insulin secretion, glucagon suppression, and energy expenditure